Antinociceptive properties of selective MT(2) melatonin receptor partial agonists

• Published in: European journal of pharmacology 2015-10, Vol.764, p.424-432
• Main Authors: López-Canul, Martha, Comai, Stefano, Domínguez-López, Sergio, Granados-Soto, Vinicio, Gobbi, Gabriella
• Format: Article
• Language: English
• Subjects: Acetamides - metabolism; Acetamides - pharmacology; Acetaminophen - pharmacology; Analgesics - metabolism; Analgesics - pharmacology; Aniline Compounds - metabolism; Aniline Compounds - pharmacology; Animals; Behavior, Animal - drug effects; Brain - drug effects; Brain - metabolism; Brain - physiopathology; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Partial Agonism; Formaldehyde; Ketorolac - pharmacology; Male; Nociception - drug effects; Nociceptive Pain - chemically induced; Nociceptive Pain - metabolism; Nociceptive Pain - physiopathology; Nociceptive Pain - prevention & control; Nociceptive Pain - psychology; Protein Binding; Rats, Wistar; Receptor, Melatonin, MT2 - agonists; Receptor, Melatonin, MT2 - metabolism; Signal Transduction - drug effects; Tetrahydronaphthalenes - pharmacology; Time Factors
• ISSN: 1879-0712
• DOI: 10.1016/j.ejphar.2015.07.010

Melatonin is a neurohormone involved in the regulation of both acute and chronic pain whose mechanism is still not completely understood. We have recently demonstrated that selective MT2 melatonin receptor partial agonists have antiallodynic properties in animal models of chronic neuropathic pain by modulating ON/OFF cells of the descending antinociceptive system. Here, we examined the antinociceptive properties of the selective MT2 melatonin receptor partial agonists N-{2-[(3-methoxyphenyl)phenylamino]ethyl}acetamide (UCM765) and N-{2-[(3-bromophenyl)-(4-fluorophenyl)amino]ethyl}acetamide (UCM924) in two animal models of acute and inflammatory pain: the hot-plate and formalin tests. UCM765 and UCM924 (5-40 mg/kg, s.c.) dose-dependently increased the temperature of the first hind paw lick in the hot-plate test, and decreased the total time spent licking the injected hind paw in the formalin test. Antinociceptive effects of UCM765 and UCM924 were maximal at the dose of 20mg/kg. At this dose, the effects of UCM765 and UCM924 were similar to those produced by 200 mg/kg acetaminophen in the hot-plate test, and by 3 mg/kg ketorolac or 150 mg/kg MLT in the formalin test. Notably, antinociceptive effects of the two MT2 partial agonists were blocked by the pre-treatment with the MT2 antagonist 4-phenyl-2-propionamidotetralin (4P-PDOT, 10 mg/kg) in both paradigms. These results demonstrate the antinociceptive properties of UCM765 and UCM924 in acute and inflammatory pain models and corroborate the concept that MT2 melatonin receptor may be a novel target for analgesic drug development.